earli
diagnosi
pneumococc
pneumonia
facilit
appropri
antibiot
therapi
urinari
antigen
test
uat
known
use
diagnosi
pneumococc
pneumonia
studi
aim
evalu
use
uat
pneumococc
conjug
vaccin
era
communityacquir
pneumonia
cap
case
age
year
review
retrospect
studi
evalu
util
streptococcu
pneumonia
uat
binaxnow
assay
diagnosi
pneumococc
cap
relat
uat
posit
rate
age
comorbid
pneumonia
sever
pneumococc
serotyp
among
microbiolog
identifi
cap
case
pneumonia
common
isol
case
posit
uat
uat
posit
vari
pneumococc
serotyp
serotyp
significantli
increas
sinc
two
year
introduct
posit
rate
uat
significantli
relat
crp
level
p
lobar
pneumonia
p
age
comorbid
prior
antibiot
therapi
conclus
urinari
antigen
detect
vari
depend
pneumonia
serotyp
era
serotyp
distribut
pneumococc
pneumonia
may
chang
clinic
use
uat
need
monitor
posit
rate
uat
may
influenc
local
bacteri
burden
host
reaction
communityacquir
pneumonia
cap
major
caus
morbid
mortal
worldwid
streptococcu
pneumonia
common
caus
cap
may
lead
caus
pneumonia
unknown
etiolog
therefor
earli
diagnosi
pneumococc
pneumonia
would
facilit
appropri
antibiot
therapi
accur
diagnosi
lead
better
understand
diseas
burden
diagnosi
pneumococc
pneumonia
tradit
microbiolog
procedur
show
low
sensit
cultureproven
pneumococc
pneumonia
might
repres
portion
whole
pneumococc
pneumonia
case
time
spent
specimen
collect
perform
microbiolog
studi
previou
antibiot
use
may
part
explan
also
reason
challeng
bacteri
growth
media
antibiot
decreas
yield
etc
pneumonia
urinari
antigen
test
binax
pneumonia
assay
known
use
techniqu
rapid
simplic
reason
specif
adult
abil
detect
pneumococc
pneumonia
even
antibiot
administr
enhanc
diagnosi
pneumococc
pneumonia
even
though
urinari
antigen
test
uat
possibl
children
due
high
rate
nasopharyng
carriag
bacteria
studi
adult
shown
better
result
report
sensit
specif
although
previou
studi
support
use
uat
littl
publish
research
effect
patientand
diseasespecif
factor
patient
age
comorbid
pneumonia
sever
etc
diagnost
util
uat
pneumococci
divid
serotyp
base
capsular
polysaccharid
structur
consid
import
virul
factor
serotypespecif
differ
nasopharyng
carriag
preval
diseas
incid
observ
gave
rise
hypothesi
util
uat
would
vari
depend
pneumococc
serotyp
would
chang
posit
rate
uat
accord
chang
distribut
pneumococc
serotyp
may
occur
sinc
introduct
pneumococc
conjug
vaccin
studi
aim
evalu
proport
pneumococc
pneumonia
among
hospit
cap
use
pneumonia
uat
diagnosi
pneumococc
pneumonia
era
util
pneumonia
uat
evalu
relat
patient
age
comorbid
diseas
sever
pneumonia
serotyp
medic
record
januari
decemb
examin
select
adult
case
age
year
older
discharg
diagnosi
pneumonia
code
teach
hospit
seoul
korea
clinic
radiolog
microbiolog
find
select
record
reevalu
determin
whether
patient
fulfil
criteria
cap
describ
microbiolog
etiolog
cap
retrospect
assess
convent
laboratori
techniqu
sputum
pleura
blood
cultur
respiratori
viru
pcr
uat
patient
hospit
cap
pneumococc
pneumonia
case
select
evalu
overal
number
case
small
evalu
certain
plan
analys
especi
term
pneumonia
serotyp
miss
case
ad
microbiolog
databas
stage
studi
also
enrol
outpati
condit
met
definit
pneumococc
cap
fig
evalu
baselin
characterist
includ
case
examin
tempor
chang
uat
result
might
reflect
alter
pneumonia
serotyp
distribut
cap
patient
due
vaccin
pressur
follow
introduct
pediatr
use
analysi
defin
three
time
period
rel
introduct
period
defin
period
period
immedi
pediatr
use
began
transit
period
period
year
pediatr
use
began
period
addit
analyz
posit
rate
uat
relat
patient
age
comorbid
diseas
sever
pneumonia
serotyp
demograph
clinic
data
collect
hospit
medic
record
includ
age
sex
date
admiss
previou
use
antibiot
smoke
alcohol
consumpt
comorbid
complic
creactiv
protein
crp
procalcitonin
chest
xray
find
score
mortal
etc
definit
medic
condit
describ
previous
pneumococc
serotyp
determin
avail
isol
cap
diagnos
base
follow
definit
acut
pulmonari
infiltr
evid
chest
radiograph
consist
pneumonia
within
h
admiss
b
confirmatori
find
clinic
examin
c
acquisit
infect
outsid
hospit
patient
healthcareassoci
hospitalacquir
pneumonia
exclud
patient
cap
determin
pneumococc
pneumonia
bacterium
pneumonia
isol
blood
pleural
effus
adequ
lower
respiratori
specimen
uat
posit
case
whose
adequ
obtain
sputum
show
predomin
gramposit
diplococci
adequ
lower
respiratori
specimen
includ
transbronchi
aspir
bronchoalveolarlavag
bal
specimen
sputum
specimen
gram
stain
adequ
qualiti
wbc
squamou
epitheli
cell
per
lowpow
field
avail
pneumococc
isol
reidentifi
research
laboratori
assay
coloni
morpholog
optochin
suscept
bile
solubl
follow
reidentif
optochinsensit
bilesolubl
isol
serotyp
monoclon
antibodi
andor
pcr
use
previouslydescrib
multibead
serotyp
assay
perform
descript
analysi
comparison
examin
demograph
clinic
characterist
calcul
posit
rate
uat
relat
patientand
diseasespecif
factor
case
classifi
two
group
posit
uat
result
neg
uat
result
use
c
test
fisher
exact
test
compar
proport
categor
variabl
two
group
student
test
compar
continu
variabl
group
clinic
relev
factor
factor
show
signific
intergroup
differ
univari
analysi
includ
multivari
logist
regress
analysi
data
analyz
use
spss
version
spss
inc
chicago
il
usa
p
valu
consid
statist
signific
total
case
hospit
cap
includ
commonli
identifi
pathogen
pneumonia
account
case
tabl
exclus
cap
case
caus
unidentifi
pathogen
pneumococc
pneumonia
repres
remain
case
follow
respiratori
virus
staphylococcu
aureu
tabl
notabl
proport
pneumococc
pneumonia
among
cap
case
declin
significantli
pediatr
introduc
repres
case
case
case
case
p
total
pneumococc
pneumonia
case
enrol
baselin
characterist
summar
tabl
pneumococc
pneumonia
common
male
elderli
mean
age
year
overal
mortal
rate
increas
age
age
year
age
year
age
year
older
p
bacteremia
occur
case
bacterem
case
show
significantli
higher
mortal
rate
without
bacteremia
vs
p
case
data
avail
pneumonia
serotyp
among
case
known
serotyp
serotyp
common
follow
serotyp
tabl
use
convent
cultur
techniqu
etiolog
diagnosi
pneumonia
achiev
case
addit
case
diagnos
use
uat
analyz
tempor
chang
uat
result
found
uat
posit
rate
significantli
increas
time
show
especi
sudden
increas
period
uat
posit
rate
accord
time
period
case
case
case
p
differ
period
period
immedi
pediatr
use
p
howev
signific
differ
period
period
year
pediatr
introduct
p
fig
addit
analyz
tempor
chang
caus
serotyp
collect
avail
isol
list
tabl
proport
serotyp
tend
decreas
postpcv
period
year
introduct
compar
period
p
although
differ
signific
introduct
serotyp
decreas
serotyp
rather
increas
serotyp
frequent
isol
across
period
tabl
posit
rate
uat
vari
divers
among
case
differ
pneumococc
serotyp
fig
uat
posit
rate
serotyp
follow
serotyp
serotyp
serotyp
serotyp
serotyp
serotyp
serotyp
serotyp
serotyp
nontyp
posit
rate
uat
case
serotyp
case
serotyp
two
group
significantli
differ
uat
posit
rate
p
evalu
util
pneumonia
uat
among
case
underw
uat
pneumococc
urinari
antigen
detect
case
baselin
characterist
case
summar
tabl
case
show
posit
uat
result
significantli
higher
mean
crp
level
show
neg
uat
result
p
difficult
determin
relationship
uat
result
procalcitonin
limit
number
case
avail
data
procalcitonin
case
consid
data
period
case
avail
data
signific
differ
uat
posit
rate
accord
procalcitonin
level
p
case
lobar
pneumonia
diabet
significantli
higher
uat
posit
rate
p
p
respect
posit
rate
uat
influenc
age
sex
comorbid
complic
except
diabet
prior
antibiot
use
also
affect
uat
posit
rate
p
multivari
analysi
lobar
pneumonia
odd
ratio
ci
crp
ci
significantli
associ
differ
uat
posit
rate
addit
although
differ
signific
posit
rate
uat
show
trend
toward
increas
period
compar
period
introduct
ci
studi
proport
microbiolog
identifi
pneumococc
pneumonia
among
hospit
cap
case
case
without
inclus
uat
result
respect
find
show
rel
increas
diagnost
yield
pneumonia
addit
case
case
similar
previou
studi
show
rel
increas
diagnost
yield
rang
except
unidentifi
pathogen
pneumonia
isol
case
show
common
etiolog
pathogen
hospit
cap
thu
clinic
import
pneumonia
uat
emphas
binaxnow
pneumonia
assay
aler
waltham
usa
uat
detect
cpolysaccharid
also
known
teichoic
acid
test
commerci
approv
food
drug
administr
usa
studi
found
introduct
proport
pneumococc
pneumonia
among
total
cap
case
decreas
significantli
similar
tempor
trend
pediatr
invas
pneumococc
diseas
ipd
follow
introduct
found
mani
industri
countri
although
efficaci
data
avail
yet
korea
base
find
presum
decreas
proport
pneumococc
pneumonia
might
due
herd
effect
pediatr
vaccin
studi
period
pneumococc
vaccin
rate
adult
estim
coverag
rate
less
howev
pediatr
vaccin
rate
rate
even
higher
incomplet
vaccin
includ
korean
center
diseas
control
prevent
unpublish
data
sever
studi
shown
signific
chang
serotyp
pneumonia
nasopharyng
carriag
within
year
introduct
even
area
less
vaccin
coverag
vaccin
least
dose
herd
effect
pediatr
pneumococc
vaccin
reduc
adult
diseas
demonstr
multipl
clinic
set
posit
rate
uat
also
compar
time
period
introduct
consid
posit
rate
uat
increas
significantli
serotyp
show
decreas
tendenc
presum
posit
rate
uat
might
alter
relat
increas
nontyp
serotyp
introduct
tabl
herd
effect
even
exceed
direct
protect
benefit
immun
children
effect
especi
signific
year
vaccin
introduct
accord
previou
studi
show
alter
frequenc
patient
serotyp
introduct
chang
becam
remark
year
introduct
increas
nontyp
serotyp
occur
first
increas
nonvaccin
type
aros
later
tempor
chang
uat
posit
rate
increas
significantli
era
year
introduct
may
relat
increas
nontyp
pneumococci
decreas
capsul
product
capsular
serotyp
shift
inde
serotyp
rather
decreas
proport
nontyp
serotyp
significantli
increas
sinc
case
versu
case
versu
case
p
largescal
studi
requir
better
clarifi
relationship
capsular
serotyp
shift
uat
result
pneumococci
divid
serotyp
base
capsular
polysaccharid
produc
sinc
differ
pneumococc
serotyp
vari
tendenc
toward
nasopharyng
colon
invas
hypothesi
form
urinari
antigen
detect
would
vari
serotyp
previou
studi
suggest
capsular
polysaccharid
serotyp
less
metabol
cost
ie
fewer
carbon
atom
per
saccharid
unit
heavili
encapsul
lower
metabol
cost
capsular
polysaccharid
serotyp
includ
theoret
heavili
encapsul
serotyp
low
metabol
cost
might
abl
decreas
cpolysaccharid
exposur
therebi
rais
suspicion
serotypespecif
differ
urinari
antigen
detect
contrari
initi
hypothesi
serotyp
show
urinari
antigen
detect
rate
similar
overal
posit
rate
pneumococc
serotyp
also
show
clear
trend
toward
urinari
antigen
detect
rate
differ
overal
posit
rate
shown
fig
posit
rate
uat
variabl
pneumococc
serotyp
result
suggest
factor
besid
capsul
thick
amount
cpolysaccharid
amount
nasopharyng
carriag
rate
vaccin
pressur
may
influenc
urinari
antigen
detect
rate
studi
posit
rate
uat
rather
low
compar
previou
report
sensit
uat
report
slightli
lower
nonbacterem
pneumococc
pneumonia
bacterem
case
lower
detect
rate
urinari
antigen
studi
previou
studi
may
partli
explain
effect
fewer
bacterem
episod
studi
compar
previou
studi
although
number
studi
demonstr
util
uat
littl
inform
effect
either
host
microbiolog
factor
util
uat
particularli
term
serotyp
studi
analyz
posit
rate
uat
accord
sever
demograph
clinic
factor
demonstr
higher
crp
level
significantli
relat
higher
posit
rate
uat
case
show
lobar
pneumonia
also
associ
higher
uat
posit
rate
cpolysaccharid
pneumonia
major
ligand
crp
bind
crp
ligand
activ
classic
complement
pathway
stimul
phagocytosi
addit
pneumococc
cpolysaccharid
known
trigger
inflammatori
cytokin
releas
includ
interleukin
il
tumor
necrosi
factora
turn
induc
product
crp
consid
data
togeth
thought
like
local
bacteri
burden
diabet
mellitu
chronic
liver
diseas
chronic
pulmonari
diseas
asthma
chronic
obstruct
lung
diseas
chronic
cardiovascular
diseas
heart
failur
cardiomyopathi
chronic
condit
affect
cardiac
function
current
smoke
heavi
alcohol
use
defin
alcohol
use
day
week
diagnosi
alcohol
c
high
risk
defin
presenc
one
follow
splenic
dysfunct
includ
postsplenectomi
statu
hematolog
malign
multipl
myeloma
leukemia
lymphoma
condit
affect
bone
marrow
lymphat
system
solid
organ
stem
cell
transplant
chronic
renal
diseas
hiv
infect
highdos
corticosteroid
use
mg
day
prednison
equival
last
two
week
treatment
recombin
human
immunomodul
host
reaction
acut
phase
respons
may
influenc
urinari
antigen
detect
inde
sever
previou
studi
show
bacteremia
associ
higher
detect
urinari
antigen
posit
rate
uat
show
nonsignific
tendenc
increas
bacteremia
perhap
reflect
rel
small
number
bacterem
case
includ
present
studi
uat
result
influenc
previou
antibiot
use
similar
find
previou
studi
studi
limit
first
studi
conduct
retrospect
design
although
import
know
vaccin
statu
case
order
analyz
result
littl
inform
owe
limit
medic
record
second
limit
number
pneumococc
isol
avail
serotyp
statist
power
low
evalu
signific
differ
uat
posit
rate
among
capsular
serotyp
summari
uat
use
techniqu
detect
pneumonia
antigen
urin
sampl
increas
diagnost
yield
pneumococci
patient
cap
irrespect
prior
antibiot
therapi
result
uat
might
influenc
local
bacteri
burden
host
reaction
addit
shown
result
uat
differ
accord
pneumonia
serotyp
caus
pneumococc
pneumonia
era
pneumonia
serotyp
distribut
may
chang
clinic
use
uat
need
monitor
prospect
